Geode Capital Management LLC Raises Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Geode Capital Management LLC increased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 763,790 shares of the company’s stock after purchasing an additional 10,106 shares during the period. Geode Capital Management LLC owned 2.28% of TransMedics Group worth $119,938,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new stake in TransMedics Group in the second quarter valued at approximately $47,000. USA Financial Formulas acquired a new position in shares of TransMedics Group in the 3rd quarter valued at $55,000. Quarry LP raised its position in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares during the last quarter. National Bank of Canada FI boosted its stake in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the period. Finally, Signaturefd LLC grew its position in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Up 2.3 %

TMDX stock opened at $65.71 on Wednesday. TransMedics Group, Inc. has a 52 week low of $60.80 and a 52 week high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market cap of $2.21 billion, a P/E ratio of 69.90 and a beta of 2.06. The company’s 50-day moving average price is $92.92 and its 200 day moving average price is $130.29.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period last year, the firm earned ($0.12) EPS. TransMedics Group’s revenue was up 63.7% compared to the same quarter last year. On average, research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Robert W. Baird decreased their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Piper Sandler cut their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. TD Cowen lowered their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Finally, Canaccord Genuity Group cut their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

Insider Buying and Selling at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. The trade was a 12.27 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,417 shares of company stock valued at $2,240,738. Insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.